{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:52Z","timestamp":1786980292018,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.gtc.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:52:41Z","timestamp":1781725961000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-Severe Clostridium difficile Infection"],"prefix":"10.1016","volume":"55","author":[{"given":"Kazi I.","family":"Ullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga C.","family":"Aroniadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.gtc.2026.05.005_bib1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/521854","article-title":"Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents","volume":"45","author":"Riggs","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.005_bib2","first-page":"301","article-title":"Clostridium difficile infection and the role of adaptive immunity in the microbiome","volume":"13","author":"Fischer","year":"2017","journal-title":"Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.005_bib3","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","article-title":"Overdiagnosis of Clostridium difficile infection in the molecular test era","volume":"175","author":"Polage","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.005_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00021-17","article-title":"Understanding Clostridium difficile colonization","volume":"31","author":"Crobach","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.005_bib5","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical Practice Guideline by the infectious diseases Society of America (IDSA) and Society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.005_bib6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2026.05.005_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mimet.2017.09.015","article-title":"A two-step approach improves the diagnosis of Clostridium difficile infection","volume":"143","author":"Kachrimanidou","year":"2017","journal-title":"J Microbiol Methods"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.005_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/CMR.00016-13","article-title":"Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories","volume":"26","author":"Burnham","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.005_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1473-3099(13)70200-7","article-title":"Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection","volume":"13","author":"Planche","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.005_bib10","first-page":"371","article-title":"Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA medical center, 1982-1991","volume":"15","author":"Olson","year":"1994","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.005_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.005_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cgh.2011.09.030","article-title":"Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis","volume":"10","author":"Deshpande","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2026.05.005_bib13","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.14309\/01.ajg.0000702976.57255.60","article-title":"Proton pump inhibitor therapy and risk of Clostridium difficile Infection (CDI): a nationwide cohort study","volume":"115","author":"Trujillo","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.005_bib14","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/ajg.2013.333","article-title":"Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients","volume":"108","author":"Freedberg","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.005_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/cid\/cir301","article-title":"Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection","volume":"53","author":"Stevens","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.005_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.005_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jhin.2008.08.012","article-title":"Meta-analysis to assess risk factors for recurrent Clostridium difficile infection","volume":"70","author":"Garey","year":"2008","journal-title":"J Hosp Infect"},{"issue":"10","key":"10.1016\/j.gtc.2026.05.005_bib18","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1172\/JCI72336","article-title":"Clostridium difficile and the microbiota","volume":"124","author":"Seekatz","year":"2014","journal-title":"J Clin Investig"},{"issue":"10","key":"10.1016\/j.gtc.2026.05.005_bib19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1586\/17474124.2016.1158097","article-title":"Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection","volume":"10","author":"Khanna","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.005_bib20","article-title":"Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat? Antimicrob Steward Healthc","volume":"4","author":"Vandervelde","year":"2024","journal-title":"Epidemiol"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.005_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.005_bib22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.cmi.2024.08.003","article-title":"Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile-a German multicentre cohort study","volume":"30","author":"Conrad","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.005_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0002-9343(89)90223-4","article-title":"Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens","volume":"86","author":"Fekety","year":"1989","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.005_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.gtc.2026.05.005_bib25","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00605-12","article-title":"Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.gtc.2026.05.005_bib26","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S1473-3099(23)00047-6","article-title":"Redefining Clostridioides difficile infection antibiotic response and clinical outcomes","volume":"23","author":"Gonzales-Luna","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.005_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40121-021-00480-0","article-title":"Budget impact analysis of fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection in the United States","volume":"11","author":"Jiang","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"10","key":"10.1016\/j.gtc.2026.05.005_bib28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.cmi.2023.06.018","article-title":"A cost-utility analysis of two Clostridioides difficile infection guideline treatment pathways","volume":"29","author":"Swart","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.005_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12879-016-1786-6","article-title":"Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.gtc.2026.05.005_bib30","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1093\/cid\/cis340","article-title":"Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis","volume":"55","author":"Bauer","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.005_bib31","doi-asserted-by":"crossref","first-page":"O301","DOI":"10.1111\/1469-0691.12391","article-title":"Predicting a complicated course of Clostridium difficile infection at the bedside","volume":"20","author":"Hensgens","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.005_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/jama.2014.17103","article-title":"Diagnosis and treatment of Clostridium difficile in adults: a systematic review","volume":"313","author":"Bagdasarian","year":"2015","journal-title":"JAMA"},{"issue":"29","key":"10.1016\/j.gtc.2026.05.005_bib33","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.3748\/wjg.15.3591","article-title":"Post-infectious irritable bowel syndrome","volume":"15","author":"Thabane","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.005_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1017\/ice.2017.303","article-title":"Cost-effectiveness of competing treatment strategies for Clostridium difficile infection: a systematic review","volume":"39","author":"Le","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.gtc.2026.05.005_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2334-13-150","article-title":"Validation of the chronic disease score-infectious disease (CDS-ID) for the prediction of hospital-associated clostridium difficile infection (CDI) within a retrospective cohort","volume":"13","author":"Stevens","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.005_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7861\/clinmedicine.11-1-75","article-title":"Prevention and treatment of Clostridium difficile infection","volume":"11","author":"Gouliouris","year":"2011","journal-title":"Clin Med"},{"issue":"Suppl 3","key":"10.1016\/j.gtc.2026.05.005_bib37","first-page":"S14","article-title":"Strategies for prevention of Clostridium difficile infection","volume":"7","author":"Dubberke","year":"2012","journal-title":"J Hosp Med"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.005_bib38","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/10600280241239685","article-title":"Live biotherapeutic products for the prevention of recurrent Clostridioides difficile infection","volume":"58","author":"Pettit","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.005_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.005_bib40","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciae410","article-title":"CLOVER (CLOstridium difficile vaccine efficacy tRial) study: a phase 3, randomized trial investigating the efficacy and safety of a detoxified toxin A\/B vaccine in adults 50 years and older at increased risk of Clostridioides difficile infection","volume":"79","author":"Donskey","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.005_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1473-3099(20)30331-5","article-title":"Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial","volume":"21","author":"de Bruyn","year":"2021","journal-title":"Lancet Infect Dis"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855326000336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855326000336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:30:40Z","timestamp":1786977040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855326000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889855326000336"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2026.05.005","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Severe Clostridium difficile Infection","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}